MinervaX Hopes To Match Pfizer In Group B Streptococcus Vaccines Race
Raises €72m Ahead Of Phase III Program
The Danish biotech has secured more funding for a late-stage program to advance its vaccine against Group B streptococcus, which is in a race for approval with Pfizer's product.
